<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076149</url>
  </required_header>
  <id_info>
    <org_study_id>VX20-121-103</org_study_id>
    <secondary_id>2021-000694-85</secondary_id>
    <nct_id>NCT05076149</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of&#xD;
      VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for&#xD;
      F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or&#xD;
      have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and no&#xD;
      F508del mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24</measure>
    <time_frame>From Baseline Through Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Sweat Chloride (SwCl) Through Week 24</measure>
    <time_frame>From Baseline Through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With SwCl &lt;60 Millimole per Liter (mmol/L) Through Week 24 (Pooled With Data From Study VX20-121-102)</measure>
    <time_frame>From Baseline Through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With SwCl &lt;30 mmol/L Through Week 24 (Pooled With Data From Study VX20-121-102)</measure>
    <time_frame>From Baseline Through Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>VX-121/TEZ/D-IVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive VX-121/TEZ/D-IVA in the morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ELX/TEZ/IVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-121/TEZ/D-IVA</intervention_name>
    <description>Fixed-dose combination tablets for oral administration.</description>
    <arm_group_label>VX-121/TEZ/D-IVA</arm_group_label>
    <other_name>VX-121/VX-661/CTP-656</other_name>
    <other_name>VX-121/VX-661/VX-561</other_name>
    <other_name>VX-121/tezacaftor/deutivacaftor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELX/TEZ/IVA</intervention_name>
    <description>Fixed-dose combination tablets for oral administration.</description>
    <arm_group_label>ELX/TEZ/IVA</arm_group_label>
    <other_name>VX-445/VX-661/VX-770</other_name>
    <other_name>elexacaftor/tezacaftor/ivacaftor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA</intervention_name>
    <description>Tablet for oral administration.</description>
    <arm_group_label>ELX/TEZ/IVA</arm_group_label>
    <other_name>VX-770</other_name>
    <other_name>ivacaftor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (matched to VX-121/TEZ/D-IVA)</intervention_name>
    <description>Placebo matched to VX-121/TEZ/D-IVA for oral administration.</description>
    <arm_group_label>ELX/TEZ/IVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (matched to ELX/TEZ/IVA)</intervention_name>
    <description>Placebo matched to ELX/TEZ/IVA for oral administration.</description>
    <arm_group_label>VX-121/TEZ/D-IVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (matched to IVA)</intervention_name>
    <description>Placebo matched to IVA for oral administration.</description>
    <arm_group_label>VX-121/TEZ/D-IVA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Participant has one of the following genotypes:&#xD;
&#xD;
               -  Homozygous for F508del;&#xD;
&#xD;
               -  Heterozygous for F508del and a gating (F/G) mutation;&#xD;
&#xD;
               -  Heterozygous for F508del and a residual function (F/RF) mutation;&#xD;
&#xD;
               -  At least 1 other TCR CFTR gene mutation identified as responsive to ELX/TEZ/IVA&#xD;
                  and no F508del mutation&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1) value &gt;=40% and &lt;=90% of predicted mean&#xD;
             for age, sex, and height for participants currently receiving CFTR protein modulator&#xD;
             therapy; FEV1 &gt;=40% and &lt;=80% for participants not currently receiving CFTR protein&#xD;
             modulator therapy&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of solid organ or hematological transplantation&#xD;
&#xD;
          -  Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh&#xD;
             Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)&#xD;
&#xD;
          -  Lung infection with organisms associated with a more rapid decline in pulmonary status&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
        Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
    <mesh_term>Elexacaftor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

